NCT04206852 Safety and Efficacy of Balloon Pulmonary Angioplasty in China
| NCT ID | NCT04206852 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Chinese Pulmonary Vascular Disease Research Group |
| Condition | Chronic Thromboembolic Pulmonary Hypertension |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2018-05-11 |
| Primary Completion | 2028-05-11 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2018-05-11 with a primary completion date of 2028-05-11.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Balloon pulmonary angioplasty (BPA) is a potential treatment for non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH). The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA.
Eligibility Criteria
Inclusion Criteria: 1. diagnosed with CTEPH according to ESC Guidelines (1) Mean PAP ≥ 25mmHg at rest; or if mean PAP \< 25mmHg at rest, have exercise limitations from chronic thromboembolic disease (2)Abnormal ventilation perfusion lung scanning (VQ) scan, pulmonary angiogram, computer tomographic pulmonary angiogram, or magnetic resonance pulmonary angiogram confirming chronic thromboembolic disease as recommended by standard guidelines 2. Treatment with anticoagulation for ≥ 3 months before diagnosis of CTEPH 3. Not amenable to pulmonary endarterectomy 4. Willing to provide informed consent Exclusion Criteria: 1. Patients unwilling or unable to provide written consent for participation in the study. 2. Impossible to follow up.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT04206852 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Chronic Thromboembolic Pulmonary Hypertension. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04206852 currently recruiting?
Yes, NCT04206852 is actively recruiting participants. Contact the research team at zhihongliufuwai@163.com for enrollment information.
Where is the NCT04206852 trial being conducted?
This trial is being conducted at Beijing, China, Beijing, China.
Who is sponsoring the NCT04206852 clinical trial?
NCT04206852 is sponsored by Chinese Pulmonary Vascular Disease Research Group. The trial plans to enroll 200 participants.